In yet another example of an interesting public private partnership within bioscience sector, the pharma major Zydus Cadila and the Council of Scientific and Industrial Research (CSIR)-Institute of Microbial Technology (IMTECH) have signed an agreement to identify new drug candidates for treatment of drug resistant infections.
The research partnership will primarily aim to identify new drug candidates for treatment of drug-resistant infections.
Under the collaborative research agreement, scientists from both organisations working together on microbiology and genomics to identify new lead candidate as novel anti-tuberculosis compound.
For this project, scientists at Chandigarh based IMTECH will utilise their expertise and scientific knowledge in microbiology while Zydus Cadila will provide expertise in medicinal chemistry and pharmaceutical drug development to develop new drug combinations against drug-resistant pathogens which causes severe diseases in India and across the world.
